Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
This study has been completed.
Sponsor:
Cubist Pharmaceuticals
Collaborator:
GlaxoSmithKline
Information provided by:
Cubist Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00101998
First received: January 18, 2005
Last updated: March 6, 2009
Last verified: March 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.
| Condition | Intervention | Phase |
|---|---|---|
|
Constipation Bowel Dysfunction |
Drug: alvimopan |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects |
Resource links provided by NLM:
Further study details as provided by Cubist Pharmaceuticals:
Primary Outcome Measures:
- Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.
Secondary Outcome Measures:
- Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.
| Estimated Enrollment: | 215 |
| Study Start Date: | October 2003 |
Intervention Details:
-
Drug: alvimopan
Other Name: alvimopan
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Subject is in any stage of cancer but has a minimum life expectancy of at least 3 months at the time of the Screening Visit.
- Subject is taking opioid therapy for persistent cancer pain.
- Subject meets the definition of opioid-induced bowel dysfunction as follows: Since starting opioid therapy, the subject has had decreased BM frequency and at least one of the following constipation symptoms [sensation of incomplete evacuation, difficulty in expelling stool (straining), hard stools (abnormal stool consistency)].
- Subject understands the procedures, agrees to participate in the study, and has signed and dated the informed consent form prior to the initiation of any study-related activities, including discontinuation of pre-study laxative regimen or other prohibited medications.
- Subject is able and willing to comply with a daily paper diary and is capable of completing paper questionnaires at study visits.
Exclusion criteria:
- Subject is pregnant or lactating, or planning to become pregnant.
- Subject is not ambulatory.
- Subject has participated in another trial with an investigational drug (unapproved), device or procedure within 30 days of the Screening Visit.
- Subject is unable to eat, drink, take/hold down oral medications.
- Subject is taking opioids for the management of drug addiction.
- Subject is unable or unwilling to discontinue the use of and/or refrain from using laxatives of all types and formulation at the Screening Visit and throughout the entire study.
- Subject has severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation. This would include a subject who has reported no bowel movement for 7 consecutive days prior to the Screening Visit.
- Subject with gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.
- Subject is currently taking vinca alkyloids or plans to take vinca alkyloids during the study.
- Subject is currently undergoing abdominal radiation therapy and/or plans to undergo abdominal radiation therapy during the study.
- Subject is HIV-infected, has active hepatitis (any subtype including ongoing chronic hepatitis B), or has ever been infected with hepatitis C.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00101998
Hide Study Locations
Hide Study LocationsLocations
| United States, Arizona | |
| GSK Investigational Site | |
| Tucson, Arizona, United States, 85723 | |
| United States, Arkansas | |
| GSK Investigational Site | |
| Hot Springs, Arkansas, United States, 71913 | |
| United States, California | |
| GSK Investigational Site | |
| Duarte, California, United States, 91010 | |
| GSK Investigational Site | |
| Fountain Valley, California, United States, 92708 | |
| GSK Investigational Site | |
| Fresno, California, United States, 93720 | |
| GSK Investigational Site | |
| La Verne, California, United States, 91750 | |
| GSK Investigational Site | |
| Los Angeles, California, United States, 90057 | |
| GSK Investigational Site | |
| Los Gatos, California, United States, 95032 | |
| GSK Investigational Site | |
| Modesto, California, United States, 95355 | |
| GSK Investigational Site | |
| Sacramento, California, United States, 95819 | |
| GSK Investigational Site | |
| San Diego, California, United States, 92120 | |
| GSK Investigational Site | |
| San Diego, California, United States, 92103 | |
| GSK Investigational Site | |
| Santa Monica, California, United States, 90403 | |
| United States, Colorado | |
| GSK Investigational Site | |
| Denver, Colorado, United States, 80210 | |
| United States, District of Columbia | |
| GSK Investigational Site | |
| Washington, District of Columbia, United States, 20010 | |
| GSK Investigational Site | |
| Washington, District of Columbia, United States, 20007 | |
| United States, Florida | |
| GSK Investigational Site | |
| Gainesville, Florida, United States, 32604 | |
| GSK Investigational Site | |
| Inverness, Florida, United States, 34452 | |
| GSK Investigational Site | |
| Lecanto, Florida, United States, 34461 | |
| GSK Investigational Site | |
| Miami Shores, Florida, United States, 33138 | |
| GSK Investigational Site | |
| New Port Richey, Florida, United States, 34653 | |
| GSK Investigational Site | |
| New Port Richey, Florida, United States, 34652 | |
| GSK Investigational Site | |
| Ocala, Florida, United States, 34474 | |
| GSK Investigational Site | |
| Palm Harbor, Florida, United States, 34684 | |
| GSK Investigational Site | |
| Stuart, Florida, United States, 34996 | |
| GSK Investigational Site | |
| Tampa, Florida, United States, 33612-9497 | |
| GSK Investigational Site | |
| Titusville, Florida, United States, 32796 | |
| United States, Georgia | |
| GSK Investigational Site | |
| Decatur, Georgia, United States, 30033 | |
| United States, Illinois | |
| GSK Investigational Site | |
| Chicago, Illinois, United States, 60610 | |
| United States, Iowa | |
| GSK Investigational Site | |
| West Des Moines, Iowa, United States, 50265 | |
| United States, Kansas | |
| GSK Investigational Site | |
| Hutchinson, Kansas, United States, 67502 | |
| United States, Maryland | |
| GSK Investigational Site | |
| Baltimore, Maryland, United States, 21218 | |
| GSK Investigational Site | |
| Baltimore, Maryland, United States, 21229-5299 | |
| GSK Investigational Site | |
| Baltimore, Maryland, United States, 21239 | |
| GSK Investigational Site | |
| Bethesda, Maryland, United States, 20817 | |
| United States, Massachusetts | |
| GSK Investigational Site | |
| Boston, Massachusetts, United States, 02115 | |
| GSK Investigational Site | |
| Boston, Massachusetts, United States, 02215 | |
| GSK Investigational Site | |
| Worcester, Massachusetts, United States, 01608 | |
| United States, Michigan | |
| GSK Investigational Site | |
| Ann Arbor, Michigan, United States, 48109 | |
| GSK Investigational Site | |
| Flint, Michigan, United States, 48503 | |
| United States, Minnesota | |
| GSK Investigational Site | |
| St. Louis Park, Minnesota, United States, 55426 | |
| United States, Missouri | |
| GSK Investigational Site | |
| Kansas City, Missouri, United States, 64114 | |
| GSK Investigational Site | |
| St. Louis, Missouri, United States, 63141 | |
| United States, Nevada | |
| GSK Investigational Site | |
| Reno, Nevada, United States, 89502 | |
| United States, New Mexico | |
| GSK Investigational Site | |
| Albuquerque, New Mexico, United States, 87109 | |
| United States, New York | |
| GSK Investigational Site | |
| Bethpage, New York, United States, 11714 | |
| GSK Investigational Site | |
| Huntington Station, New York, United States, 11746 | |
| GSK Investigational Site | |
| Jamaica, New York, United States, 11432 | |
| United States, North Carolina | |
| GSK Investigational Site | |
| Chapel Hill, North Carolina, United States, 27599 | |
| GSK Investigational Site | |
| Charlotte, North Carolina, United States, 28209 | |
| GSK Investigational Site | |
| Durham, North Carolina, United States, 27710 | |
| GSK Investigational Site | |
| Hendersonville, North Carolina, United States, 28793 | |
| GSK Investigational Site | |
| Raleigh, North Carolina, United States, 27606 | |
| GSK Investigational Site | |
| Winston-Salem, North Carolina, United States, 27103 | |
| United States, North Dakota | |
| GSK Investigational Site | |
| Bismarck, North Dakota, United States, 58501 | |
| GSK Investigational Site | |
| Bismarck, North Dakota, United States, 58503 | |
| United States, Ohio | |
| GSK Investigational Site | |
| Canton, Ohio, United States, 44718 | |
| GSK Investigational Site | |
| Middletown, Ohio, United States, 45042 | |
| United States, Oregon | |
| GSK Investigational Site | |
| Portland, Oregon, United States, 97225 | |
| United States, Tennessee | |
| GSK Investigational Site | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Texas | |
| GSK Investigational Site | |
| Amarillo, Texas, United States, 79106 | |
| GSK Investigational Site | |
| Houston, Texas, United States, 77030 | |
| GSK Investigational Site | |
| Webster, Texas, United States, 77598 | |
| United States, Virginia | |
| GSK Investigational Site | |
| Norfolk, Virginia, United States, 23507 | |
| GSK Investigational Site | |
| Portsmouth, Virginia, United States, 23704 | |
| GSK Investigational Site | |
| Richmond, Virginia, United States, 23249 | |
| GSK Investigational Site | |
| Richmond, Virginia, United States, 23298-5028 | |
| United States, Washington | |
| GSK Investigational Site | |
| Tacoma, Washington, United States, 98405 | |
| United States, Wisconsin | |
| GSK Investigational Site | |
| Milwaukee, Wisconsin, United States, 53215 | |
| Argentina | |
| GSK Investigational Site | |
| Capital Federal, Buenos Aires, Argentina, C1405CUB | |
| GSK Investigational Site | |
| Rosario, Santa Fe, Argentina, 2000 | |
| Australia, New South Wales | |
| GSK Investigational Site | |
| St Leonards, New South Wales, Australia, 2065 | |
| Australia, Queensland | |
| GSK Investigational Site | |
| Redcliffe, Queensland, Australia, 4020 | |
| GSK Investigational Site | |
| South Brisbane, Queensland, Australia, 4101 | |
| Australia, South Australia | |
| GSK Investigational Site | |
| Daw Park, South Australia, Australia, 5041 | |
| Australia, Victoria | |
| GSK Investigational Site | |
| Malvern, Victoria, Australia, 3144 | |
| Canada, Manitoba | |
| GSK Investigational Site | |
| Winnipeg, Manitoba, Canada, R3A 1R9 | |
| Canada, Newfoundland and Labrador | |
| GSK Investigational Site | |
| Saint John's, Newfoundland and Labrador, Canada, A1B 3V6 | |
| Canada, Ontario | |
| GSK Investigational Site | |
| Kitchener, Ontario, Canada, N2G 1G3 | |
| GSK Investigational Site | |
| London, Ontario, Canada, N6A 4L6 | |
| GSK Investigational Site | |
| North Bay, Ontario, Canada, P1B 2H3 | |
| GSK Investigational Site | |
| Oshawa, Ontario, Canada, L1G 2B9 | |
| GSK Investigational Site | |
| Sudbury, Ontario, Canada, P3E 5J1 | |
| Canada, Quebec | |
| GSK Investigational Site | |
| Bonaventure, Quebec, Canada, G0C 1E0 | |
| GSK Investigational Site | |
| Chandler, Quebec, Canada, G0C 1K0 | |
| GSK Investigational Site | |
| Levis, Quebec, Canada, G6V 3Z1 | |
| GSK Investigational Site | |
| Montreal, Quebec, Canada, H1T 2M4 | |
| GSK Investigational Site | |
| Sherbrooke, Quebec, Canada, J1H 1Z1 | |
| Canada | |
| GSK Investigational Site | |
| Quebec, Canada, G1R 2J6 | |
| Czech Republic | |
| GSK Investigational Site | |
| Brno, Czech Republic, 625 00 | |
| GSK Investigational Site | |
| Brno, Czech Republic, 656 91 | |
| GSK Investigational Site | |
| Plzen, Czech Republic, 304 60 | |
| GSK Investigational Site | |
| Praha 10, Czech Republic, 100 34 | |
| Finland | |
| GSK Investigational Site | |
| Helsinki, Finland, 00029 | |
| France | |
| GSK Investigational Site | |
| Bordeaux Cedex, France, 33076 | |
| GSK Investigational Site | |
| Vandoeuvre-Les-Nancy, France, 54511 | |
| GSK Investigational Site | |
| Villejuif Cedex, France, 94805 | |
| Germany | |
| GSK Investigational Site | |
| Goettingen, Niedersachsen, Germany, 37073 | |
| GSK Investigational Site | |
| Goslar, Niedersachsen, Germany, 38642 | |
| Hong Kong | |
| GSK Investigational Site | |
| Kwun Tong, Hong Kong | |
| GSK Investigational Site | |
| Pokfulam, Hong Kong | |
| GSK Investigational Site | |
| Shatin, Hong Kong | |
| Hungary | |
| GSK Investigational Site | |
| Budapest, Hungary, 1529 | |
| GSK Investigational Site | |
| Budapest, Hungary, 1097 | |
| GSK Investigational Site | |
| Miskolc, Hungary, 3529 | |
| GSK Investigational Site | |
| Zalaegerszeg-Pozva, Hungary, 8900 | |
| India | |
| GSK Investigational Site | |
| Bangalore, India, 560 034 | |
| Italy | |
| GSK Investigational Site | |
| Caserta, Campania, Italy, 81100 | |
| GSK Investigational Site | |
| Napoli, Campania, Italy, 80131 | |
| GSK Investigational Site | |
| Forlì, Emilia-Romagna, Italy, 47100 | |
| GSK Investigational Site | |
| Rimini, Emilia-Romagna, Italy, 47900 | |
| GSK Investigational Site | |
| Genova, Liguria, Italy, 16132 | |
| GSK Investigational Site | |
| Milano, Lombardia, Italy, 20127 | |
| GSK Investigational Site | |
| Pavia, Lombardia, Italy, 27100 | |
| GSK Investigational Site | |
| Busca (CN), Piemonte, Italy, 12022 | |
| GSK Investigational Site | |
| Novara, Piemonte, Italy, 28100 | |
| GSK Investigational Site | |
| Catania, Sicilia, Italy, 95124 | |
| GSK Investigational Site | |
| Firenze, Toscana, Italy, 50139 | |
| Korea, Republic of | |
| GSK Investigational Site | |
| Seoul, Korea, Republic of, 152-703 | |
| GSK Investigational Site | |
| Seoul, Korea, Republic of, 137-701 | |
| Netherlands | |
| GSK Investigational Site | |
| Leeuwarden, Netherlands, 8934 AD | |
| New Zealand | |
| GSK Investigational Site | |
| Dunedin, New Zealand, 9001 | |
| GSK Investigational Site | |
| Hastings, New Zealand, 4201 | |
| GSK Investigational Site | |
| Wellington, New Zealand, 6002 | |
| Pakistan | |
| GSK Investigational Site | |
| Lahore, Pakistan, 54600 | |
| Peru | |
| GSK Investigational Site | |
| Lima, Peru, Lima 34 | |
| GSK Investigational Site | |
| Lima, Peru, Lima 11 | |
| Philippines | |
| GSK Investigational Site | |
| Manila, Philippines, 1000 | |
| Poland | |
| GSK Investigational Site | |
| Bialystok, Poland, 15-540 | |
| GSK Investigational Site | |
| Olsztyn, Poland, 10-228 | |
| GSK Investigational Site | |
| Otwock, Poland, 05-400 | |
| GSK Investigational Site | |
| Poznan, Poland, 60-569 | |
| Portugal | |
| GSK Investigational Site | |
| Lisboa, Portugal, 1800 | |
| GSK Investigational Site | |
| Lisboa, Portugal, 1069-166 Lisboa | |
| GSK Investigational Site | |
| Lisboa, Portugal, 1070 | |
| Russian Federation | |
| GSK Investigational Site | |
| Moscow, Russian Federation, 117216 | |
| GSK Investigational Site | |
| Moscow, Russian Federation, 127018 | |
| GSK Investigational Site | |
| Moscow, Russian Federation, 119048 | |
| GSK Investigational Site | |
| St'Petersburg, Russian Federation, 195247 | |
| South Africa | |
| GSK Investigational Site | |
| Durban, KwaZulu- Natal, South Africa, 4001 | |
| GSK Investigational Site | |
| Groenkloof, Pretoria, South Africa | |
| GSK Investigational Site | |
| Houghton, Johannesburg, South Africa, 2000 | |
| GSK Investigational Site | |
| Kenilworth, Cape Town, South Africa, 7745 | |
| Spain | |
| GSK Investigational Site | |
| Alcorcon, Spain, 28922 | |
| GSK Investigational Site | |
| Barcelona, Spain, 08036 | |
| GSK Investigational Site | |
| Barcelona, Spain, 08023 | |
| GSK Investigational Site | |
| Cordoba, Spain, 14004 | |
| GSK Investigational Site | |
| Granada, Spain, 18012 | |
| GSK Investigational Site | |
| Jaén, Spain, 23007 | |
| GSK Investigational Site | |
| Madrid, Spain, 28006 | |
| GSK Investigational Site | |
| Sabadell / Barcelona, Spain | |
| GSK Investigational Site | |
| Serra / Valencia, Spain | |
| GSK Investigational Site | |
| Sevilla, Spain, 41014 | |
| GSK Investigational Site | |
| Soria, Spain, 42002 | |
| GSK Investigational Site | |
| Valencia, Spain, 46010 | |
| Taiwan | |
| GSK Investigational Site | |
| Taipei, Taiwan, 100 | |
| Thailand | |
| GSK Investigational Site | |
| Chiang Mai, Thailand, 50200 | |
| United Kingdom | |
| GSK Investigational Site | |
| London, United Kingdom, SW3 6JJ | |
| GSK Investigational Site | |
| Newcastle-upon-Tyne, United Kingdom, NE4 6BE | |
| GSK Investigational Site | |
| Nottingham, United Kingdom, NG5 1PB | |
| GSK Investigational Site | |
| Sheffield, United Kingdom, S10 2JF | |
| GSK Investigational Site | |
| Surrey, United Kingdom, SM2 5PT | |
Sponsors and Collaborators
Cubist Pharmaceuticals
GlaxoSmithKline
Investigators
| Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
More Information
No publications provided
| Responsible Party: | Study Director, GSK |
| ClinicalTrials.gov Identifier: | NCT00101998 History of Changes |
| Obsolete Identifiers: | NCT00903513 |
| Other Study ID Numbers: | 767905/008 |
| Study First Received: | January 18, 2005 |
| Last Updated: | March 6, 2009 |
| Health Authority: | United States: Food and Drug Administration France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Cubist Pharmaceuticals:
|
OBD (Induced Bowel Dysfunction) cancer pain pain medication |
constipation bowel bowel dysfunction |
Additional relevant MeSH terms:
|
Constipation Intestinal Diseases Gastrointestinal Diseases Signs and Symptoms, Digestive Signs and Symptoms Digestive System Diseases Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013